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Telomere length and survival in 
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patients
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Telomere repeats at chromosomal ends, critical to genomic integrity, undergo age-dependent attrition. 
Telomere length, a polygenic trait, has been associated with risk of several disorders including cancers. 
In contrast to association of long telomeres with increased risk of several cancers, including melanoma, 
emerging reports suggest that short telomeres predict poor survival in patients with different cancers. 
In this study based on 1019 stage I and II cutaneous melanoma patients, we show an association 
between the patients with short telomeres and poor melanoma-specific survival (HR 2.05, 95% CI 1.33–
3.16) compared to patients with long telomeres. Due to inverse correlation between age and telomere 
length (r -0.19, P < 0.0001), we stratified the patients into quantiles based on age at diagnosis and also 
carried out age-matched analysis. The effect of short telomeres on survival was determined by using 
multivariate Cox regression that included composite genetic risk score computed from genotyping of 
the patients for telomere-length associated polymorphisms. The effect of decreased telomere length 
on poor melanoma-specific survival was particularly strong in patients within the age quantile below 
30 years (HR 3.82, 95% CI 1.10–13.30) and between 30–40 years (HR 2.69, 95% CI 1.03–7.03). Our 
study shows that in contrast to increased melanoma risk associated with increased telomere length, 
decreased telomere length predicts poor survival in melanoma subgroups.
Cutaneous melanoma with its propensity to metastasize and intrinsic drug resistance remains causal for the 
majority of skin cancer related deaths1,2. Despite increase in the range of treatments, including targeted and 
immunotherapies, for eliciting stable response in patients with metastatic melanoma, the long term prospects in 
terms of treatment remain confined to disease management3. The search for the factors that can identify patients 
at early stages at risk of poor survival remains crucial in melanoma. The known markers of poor outcome in mel-
anoma include increased Breslow thickness, presence of tumor ulceration, increased tumor mitotic rate, reduced 
nevus number and the presence of locoregional or distant metastasis at diagnosis4–8. The melanoma genome in 
general is characterized by one of the highest prevalence of somatic mutations in human cancers and several 
genetic alterations have been shown to predict outcome in melanoma9–13. In particular, the most frequent somatic 
mutations in cutaneous melanoma like those in the TERT promoter and BRAF/NRAS reportedly associate with 
poor disease-free and melanoma-specific survival9,14.
Telomere repeats at chromosomal ends, critical to genomic integrity, are maintained through an elaborate net-
work of proteins and pathways15,16. In humans, TTAGGG repeats account for telomere length that ranges between 
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10–15 kb17. Inherent limitations of DNA replication and telomerase suppression in most somatic cells through 
epigenetic reprogramming of the telomerase reverse transcriptase (TERT) gene, cause telomeres to undergo 
age-dependent incremental attrition16,18. Telomere shortening is further influenced by oxidative damage and rep-
licative stress caused by genetic, epigenetic and environmental factors15,19. However, in most cancers enhanced 
TERT transcription, due to various mechanisms, and consequent telomerase rejuvenation, imparts tumor cells 
an infinite capability to surmount proliferative barrier through telomere stabilization16,20,21. Constitutive telomere 
length, a polygenic trait with high estimated heritability, has hitherto been demonstrated to be associated with 
nine different loci, with six harboring genes related to telomere homeostasis22–25. Epidemiological data, in general, 
support an association, with varying magnitudes, between constitutive telomere length and various disorders 
including cancers26,27. Different investigations over the years, in contrast, have suggested that short telomeres 
associate with poor patient survival26,28,29.
To test the association between telomere length and melanoma-specific patient survival, we measured tel-
omere length in constitutive DNA from 1019 incident cutaneous melanoma patients with stage I and II disease. 
We also used telomere length associated polymorphisms to generate composite genetic score for association 
with the disease outcome. Despite a confounding effect of the age at diagnosis, our results suggest an association 
between short telomeres and poor patient survival, particularly for melanoma patients in younger age groups.
Results
Relative telomere length and melanoma-specific survival. The study included 1019 patients 
with AJCC stage I and II cutaneous melanoma. Patients with stage 0, III and IV were excluded from the study 
(Supplementary Fig. 1). The median age at diagnosis was 52 years [IQR: 39–66] with 463 (45.4%) men and 556 
(54.6%) women. Median relative telomere length (represented as the ratio of telomere to single copy gene, T/S) 
in leukocytes, measured successfully in 995 patients, was 1.20 [inter-quartile range, IQR: 0.96–1.48]. The median 
follow-up period following the disease diagnosis was 103 months [IQR 60.62–155.11]. Of the 1019 patients, 97 
(9.5%) had died due to melanoma. The remaining 922 patients (90.5%) were censored either at their last follow-up 
date (840 patients) or at death from unrelated causes (82 patients; Supplementary Table S1).
The patients included in the study were further genotyped for rs1317082, rs7726159 and rs6060627 polymor-
phisms that have been shown to associate with telomere length in genome wide association studies30. Since the 
risk prediction varied with individual polymorphisms, a weighted genetic score was computed based on genotype 
data (Supplementary Table S2). The computed weighted genetic risk score due to genotypes with variant alleles 
for three polymorphisms ranged from −0.34 to 0.39 for rs1317082, −0.61 to 0.00 for rs7726159 and −0.46 to 
0.20 for rs6060627 (Supplementary Table S2). The composite genetic risk score, computed for each individual as 
a sum of weighted scores for all the three polymorphisms, ranged from −1.41 to 0.59 (Median: 0.00; IQR: −0.18 
to 0.20).
In univariate Cox regression analysis with telomere length as a continuous variable, an improved 
melanoma-specific patient survival was observed with increased telomere length (HR 0.65, 95% CI 0.42–1.00, 
P 0.05). The telomere data was transformed by taking the natural log of telomere length. On this scale, the 
effect of each positive unit of ln(telomere length) was estimated to have a HR of 0.46 (95% CI 0.26–0.81) on 
melanoma-specific survival. The data analysis with telomere length as a dichotomous variable based on median 
distribution also showed that the patients with short telomeres (≤1.20) were at risk of poor survival (log rank P 
0.001; HR 2.05, 95% CI 1.33–3.16, Fig. 1) compared to the patients with long telomeres (>1.20). A similar analysis 
with telomere length as categorical variable based on quartile distribution showed that the patients in the first 
quartile compared to those in the fourth quartile (longest telomeres) had the worst survival (HR 2.73, 95% CI 
1.47–5.07) followed by patients in the second quartile (HR 1.71, 95% CI 0.88–3.32) and the third quartile (HR 
1.42, 95% CI 0.72–2.82).
Other factors that affected patient survival as determined by Kaplan-Meier and univariate Cox regression 
analyses included age at diagnosis (P < 0.0001), sex (log rank P 0.0006), nevus count (log rank P 0.03), tumor 
location (log rank P 0.0005), tumor stage (log rank P < 0.0001), Breslow thickness (log rank P < 0.0001) and 
Figure 1. Kaplan-Meier analysis of differences in survival of patients with stage I and II melanoma based on 
telomere length. Patients were divided into two groups with short (≤1.20) and long (>1.20) telomeres based on 
median distribution. The numbers of patients at risk in each category, at respective survival intervals, are shown 
underneath.
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tumor ulceration (log rank P < 0.0001) (Supplementary Table S1). Since tumor stage is defined by Breslow 
thickness, presence/absence of ulceration and tumor mitotic rate, for multivariate analysis only tumor stage was 
included in the model.
As a continuous variable increased composite genetic risk score showed a statistically significant association 
with poor melanoma-specific survival (HR for per unit of score: 2.94, 95% CI 1.54–5.62). Similarly, a dichoto-
mous model showed that the patients with higher than median composite genetic risk score (>0) were associated 
with poor melanoma-specific survival compared to patients with lower than median genetic risk score (log rank 
P 0.02; HR 1.67, 95% CI 1.12–2.49, Fig. 2a). Segregation of patients based on composite risk score and telomere 
length into 4 categories, showed that the patient group under high-risk category with short telomeres carried 
the highest risk for mortality (HR 4.28, 95% CI 1.97–9.28) followed by patients in low-risk category with short 
telomeres (HR 3.13, 95% CI 1.43–6.88), high-risk category with long telomeres (HR 2.51, 95% CI 1.10–5.74) 
compared to the low-risk category with long telomeres (Log rank P 0.001, Fig. 2b).
Telomere-length and patient age at diagnosis. We observed a statistically significant inverse corre-
lation (Pearson correlation r −0.19, P < 0.0001) between telomere length and the patient age at diagnosis. A 
statistically significant interaction (P interaction 0.05) was also observed in the survival analysis that included 
age, telomere length and age*telomere length interaction term. With inclusion of age in the model, the associ-
ation between decreased telomere length and survival was no longer statistically significant (HR 1.50, 95% CI 
0.96–2.34). None of the other confounders individually affected the association between telomere length and 
patient survival (data not shown). Therefore, patients were stratified into quantiles based on the age and the 
effect of telomere length on melanoma-specific survival was measured using the median telomere length for 
each subgroup separately. The results showed that the patients below 30 years of age at diagnosis (first quantile) 
with short telomeres were at risk of poor survival (HR 3.91, 95% CI 1.25–12.29) compared to the patients with 
long telomeres within that sub-group. The corresponding HR for poor survival for patients with short telomeres 
compared to patients with long telomeres in the second quantile (30–40 years) was 2.89 (95% CI 1.20–6.91). For 
the third quantile (40–50 years), the corresponding HR was 2.13 (95% CI 1.13–3.99). The association between 
Figure 2. Kaplan-Meier analysis of difference in survival in patients with Stage I and II melanoma; (a) after 
stratification based on the median distribution of composite weighted genetic score; (b) after stratification into 
four sub-groups based on median distributions of composite weighted genetic score and telomere length (i) 
with composite genetic score ≤0 and long telomeres (ii) with composite genetic score >0 and long telomeres 
(iii) with composite genetic score ≤0 and short telomeres and (iv) with composite genetic score >0 and short 
telomeres. The numbers of patients at risk in each category are shown underneath at the respective survival 
intervals.
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patients with short telomeres and poor melanoma-specific survival in the fourth quantile (50–60 years) was also 
statistically significant (HR 1.57, 95% CI 1.00–2.47). For patients in the fifth (60–70 years) and higher quantiles, 
the similar associations were no t statistically significant (Table 1).
Multivariate analysis. Multivariate analysis that included age, composite genetic risk score, sex, nevus num-
ber, tumor localization, and tumor stage showed that the association of patients with short telomeres (compared 
to patients with long telomeres) with decreased melanoma-specific survival was not statistically significant (HR 
1.17, 95% CI 0.71–1.94, P 0.53; Table 2). A similar result was obtained using telomere length as a continuous 
variable (HR 0.95, 95% CI 0.67–1.36, P 0.79) and after transformation into log-scale, the HR for the effect of long 
telomeres on survival was 0.92 (95% CI 0.52–1.62, P 0.76). However, the increased composite genetic risk-score, 
in the multivariate model, was a statistically significant independent prognostic factor for poor survival (HR 
2.75, 95% CI 1.34–5.62). Additionally, the patients with nevus count >50 showed better survival (HR 0.54, 95% 
CI 0.21–1.38, P 0.20) than those with nevus count <50 (Table 2). Further, multivariate analysis using telomere 
length and composite genetic risk score as a combined variable showed that the patients under high-risk category 
with both short and long telomeres showed an increased mortality compared to patients in low-risk category with 
long telomeres (Table 3). Similarly, a multivariate model that included all confounders showed that the patients 
with short telomeres in the age group below 30 years (first quantile) were at statistically significant risk of poor 
survival (HR 3.82, 95% CI 1.10–13.30) compared to patients with long telomeres within the same group. A similar 
statistically significant association between patients with short telomeres and poor melanoma-specific survival 
was also observed in the age group 30–40 years (HR 2.69, 95% CI 1.03–7.03). The effect of telomere length on 
patient survival diminished in subsequent quantiles (Table 1).
Further we also carried age-matched analysis of the patients with “short” and “long” telomeres. Exact match-
ing of the groups (detailed in methods section) resulted in a subset of 676 patients with 338 in each group with 
a median age of 52 (Supplementary Fig. 2). Cox regression analysis on the age matched group showed that the 
patients with short telomeres compared to those with long telomere were at statistically significant risk of poor 
survival (univariate HR 1.89, 95% CI 1.10–3.25, P 0.02). Multivariate data analysis also showed in age-matched 
groups, the patients with short telomeres were at the risk of poor survival (HR 1.79, 95% CI 1.01–3.17, P 0.05; 
Table 4) compared to the patients with long telomeres.
Discussion
In this study based on stage I and II incident melanoma patients, we observed that short telomeres predis-
pose patients to poor melanoma-specific survival, which contrasts with reported association of long telomere 
with increased risk of melanoma26,31. Despite a strong inverse correlation between telomere length and age, we 
observed that the effect of short compared to long telomeres on poor survival was pronounced in patients below 
40 years at diagnosis. We also used three polymorphisms located at the TERC, TERT and BCl2L1 loci to generate 
composite genetic risk score. The polymorphisms that had been previously shown to be associated with telomere 
length and risk of various cancers through genome wide association studies did not per se show any impact on 
melanoma-specific survival in this study23,30,32. However, the use of composite genetic risk score together with 
telomere length strengthened the prediction of melanoma-specific survival in this study. Our results were further 
corroborated through use of age-matched analysis, which showed that patients with short telomeres were at a 
statistically significant poorer risk of survival than the patients with long telomeres.
Univariate analysis* Multivariate analysisƗ
Age groups Telomere lengthǂ Number Dead HR (95% CI) Number Dead HR (95% CI)¶
<30 years
Long (T/S > 1.45) 41 0 ref 36 0 ref
Short (T/S ≤ 1.45) 48 4 3.91 (1.25–12.29) 43 4 3.82 (1.10–13.30)
30–40 years
Long (T/S > 1.30) 87 4 ref 73 4 ref
Short (T/S ≤ 1.30) 91 7 2.89 (1.20–6.91) 76 4 2.69 (1.03–7.03)
40–50 years
Long (T/S > 1.27) 95 6 ref 80 4 ref
Short (T/S ≤ 1.27) 99 9 2.13 (1.13–3.99) 82 5 1.90 (0.95–3.82)
50–60 years
Long (T/S > 1.10) 98 3 ref 86 2 ref
Short (T/S ≤ 1.10) 100 6 1.57 (1.00–2.47) 90 6 1.34 (0.81–2.23)
60–70 years
Long (T/S > 1.06) 95 10 ref 81 9 ref
Short (T/S ≤ 1.06) 98 16 1.16 (0.74–1.80) 89 15 0.95 (0.58–1.54)
70–80 years
Long (T/S > 1.02) 57 11 ref 45 9 ref
Short (T/S ≤ 1.02) 59 11 0.85 (0.47–1.56) 52 9 0.67 (0.35–1.28)
>80 years
Long (T/S > 0.90) 11 3 ref 9 3 ref
Short (T/S ≤ 0.90) 16 3 0.63 (0.27–1.46) 15 2 0.47 (0.19–1.16)
Table 1. Effect of telomere-length on melanoma-specific survival in different quantiles based on patients age 
at diagnosis. *Main effects: Telomere length (P 0.02), Age (P < 0.0001); Interaction effect: telomere length*age 
(P0.05). ƗMain effects: Telomere length (P 0.03), Age (P 0.0001); Interaction effect: telomere length*age (P0.03). 
ǂTelomere length was dichotomized at median distribution of T/S ratios within corresponding age groups. 
¶Hazard ratio (HR) in multivariate model was adjusted for composite genetic risk score, gender, number of nevi, 
tumor location and tumor stage. HR values in bold indicate statistical significance (P < 0.05).
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Increased risk of melanoma due to increased telomere length has been postulated as a paradox where suffi-
cient telomere length allows cells to survive until crisis point through continuous division and consequent acqui-
sition of driver mutations33. Multiple alleles that associate with increased telomere length have been shown to 
increase the risk of various cancers27,31,34–36. Many of the variants associated with constitutive telomere length have 
been shown to functionally increase telomerase levels37,38. However, it is the critically short telomeres that trigger 
events leading to genomic instability through end-to-end chromosomal fusion with ultimate emergence of cells 
from crisis through increased telomerase levels39,40. As shown in this and earlier studies, the shorter telomeres 
tend to associate with poor survival41. In previous studies on breast cancer, multiple myeloma and renal cell carci-
noma, short telomeres were shown to be associated with poor overall survival41–44. Similarly, decreased telomere 
length was reported to be independently associated with worst survival in patients with idiopathic pulmonary 
fibrosis; longer donor leukocyte telomere length associated with increase five year survival in patients receiv-
ing hematopoietic cell transplantation for severe aplastic anemia but not for patients with acute leukemia45–47. 
Reduced telomere length in general, in a large prospective study, was shown to be associated with increased risk 
of infections48.
The observed association of short telomeres with poor melanoma-specific survival seems to be in conformity 
with emerging data49. Studies have shown that despite ubiquitous telomerase rejuvenation, a continued shorten-
ing of telomeres in tumor cells, particularly in presence of the TERT promoter mutations, in the initial stages lead 
to chromosomal fusions and aneuploidy21,49. Longer telomeres afford ample time for continued cell division until 
telomerase rejuvenation and telomere stabilization, hence the association with increased risk. In contrast, once a 
patient has developed the disease, it is the shorter telomeres in tumors that would presumably lead to rapid chro-
mosomal fusions and aneuploidy resulting in observed poor outcome49,50. Evidence suggests that genetic insta-
bility drives tumorigenesis51. Distinct types of aneuploidy predict two main hallmarks of cancer, cell proliferation 
and immune evasion; tumor aneuploidy was reported to correlate inversely with patient survival in clinical trials 
of immune checkpoint blockade anti-CTLA-4 therapy for metastatic melanoma52.
Previously, we have shown that the TERT promoter mutations associated with poor survival in patients with 
primary melanoma and our subsequent data showed shorter telomeres in tumors with than without the TERT 
promoter mutations9,53–55. In this study, telomere length was measured in blood cells and not in tumor tissues; 
therefore, the association of short telomere length with decreased survival cannot be directly explained by an 
effect in tumor cells. The telomere attrition in blood leukocytes has been considered as a marker of biological 
age and also associated with immune dysfunctions56,57. However, we lacked data on immune competency for the 
patients included in the study to investigate any such correlation.
N Dead HR (95% CI) P
Telomere length
Long (ratio >1.20) 405 25 ref
Short (ratio ≤1.20) 452 51 1.17 (0.71–1.94) 0.53
Composite genetic risk score (continuous) 857 76 2.75 (1.34–5.62) 0.006
Age at diagnosis (continuous) 857 76 1.03 (1.02–1.05) 0.0001
Sex
Males 389 43 ref
Females 468 33 0.75 (0.45–1.23) 0.25
Nevus count
<50 731 71 ref
>50 126 5 0.54 (0.21–1.38) 0.20
Tumor location
Axial 476 50 ref
Extremities 322 17 0.57 (0.32–1.02) 0.06
Acral/Mucosal 59 9 1.00 (0.47–2.12) 1.00
Tumor stage*
1 (1A, 1B) 616 27 ref
2 (2A, 2B, 2C) 241 49 4.05 (2.49–6.60) <0.0001
Table 2. Multivariate Cox analysis of the effect of telomere-length on melanoma-specific survival. *As tumor 
stage is defined by Breslow thickness, presence/absence of ulceration and tumor mitotic rate, therefore only 
tumor stage was included in the analysis.
Composite genetic risk 
score/Telomere length* N Dead HR (95% CI)Ɨ P
Telomere length
Low risk + long telomeres 208 8 ref
Low risk + short telomeres 239 24 1.74 (0.78–3.99) 0.17
High risk + long telomeres 197 17 2.41 (1.04–5.61) 0.04
High risk + short telomeres 213 27 2.19 (0.97–4.91) 0.06
Table 3. Multivariate analysis of the effect of telomere length and composite genetic risk score on melanoma-
specific survival. *The composite genetic risk score was dichotomized at median distribution (low risk ≤ 0 and 
high risk > 0). The telomere length was dichotomized at median distribution of T/S ratios (long > 1.20 and 
short ≤ 1.20). ƗHazard ratio (HR) was adjusted for age at diagnosis, gender, number of nevi, tumor location and 
tumor stage.
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In this study, however, we show that in contrast to the association between long telomeres and increased 
melanoma risk, short telomeres predict poor melanoma-specific survival. Other factors that associated with poor 
survival, besides age at diagnosis, included sex, tumor stage, and reduced nevus count. While increased nevus 
number is an established a risk factor in melanoma, an earlier report had also shown that high nevus count 
confers a favorable outcome in melanoma5,58. One report also linked increased nevus number with longer tel-
omeres59. With age as a strong confounder, the risk of poor survival due to short telomeres on survival was in par-
ticularly pronounced in younger patients. However, it may be pointed out that the telomere length can be affected 
a number of other factors including chronic diseases60,61. The lack of relevant data on those factors remains a 
weakness of the present study and requires cautious interpretation of the results.
Methods
Patient material. The patients included in the present study came from the database maintained at the 
Instituto Valenciano de Oncologia, a referral skin cancer center for the provinces of Valencia, Alicante and 
Castellon with a catchment population of approximately 5 million. The database contained a total of 2471 mel-
anoma patients. The number of incident cases recruited between 200 and 2014 was 1712. For this study we 
included incident cases from which we excluded stage 0 (298 patients), stage III (294 patients), stage IV (31 
patients) and 30 patients with melanoma at extra-cutaneous sites. All cases had been staged including lymph node 
biopsy. Thus, for this study 1059 patients with localized invasive stage I and II melanoma were eligible; however 
for 40 patients, blood samples were not available. At the end we included 1019 incident cases with histologically 
confirmed stage I and II melanoma (Supplementary Fig. 1).
Blood samples from the selected patients at the time of diagnosis were collected after informed patient consent 
between 2000 and 2014 and information remains documented in the departmental database. The patients also pro-
vided informed consent to the use of their clinical records in this study. Clinical and pathological data from patients 
were collected since January 2000 through the review of medical history, personal interview, and clinical examination 
by expert dermatologists (EN and CR) at the first visit. The available patient information included details about the 
patient age at diagnosis, sex, nevus count, tumor location, tumor stage, Breslow thickness, tumor ulceration, tumor 
mitotic rate, histology, lentigines, non-melanoma skin cancer, tumor regression, and smoking (Supplementary Table 1).
The study was approved by the IVO Ethics Committee and all methods were performed in accordance with 
the relevant guidelines and regulations. DNA from blood was extracted using standard kits (Qiagen).
Relative telomere length measurement. The relative telomere length (TL) was measured in DNA from 
peripheral blood leucocytes using a monochrome multiplex quantitative real-time PCR (MMqPCR) method that 
compares telomere repeat copy number (T) to the copy number of a single-copy gene, albumin (S). The relative 
TL in a given DNA sample was calculated as a corresponding T/S ratio62,63. Each MMqPCR optical 384-well reac-
tion plate contained DNA in triplicates from blood leucocytes, standard DNA and non-template controls. The 
standard DNA was obtained by pooling the leucocyte genomic DNA from 15 healthy individuals (40–50 years of 
age). A two-fold serial dilution of standard DNA in seven concentrations (30 ng to 0.47 ng) was used in each plate 
for quantification. The PCR reaction was performed in a 10 μL reaction volume using 2 μL of 5 × HOT FIREPol 
Probe qPCR Mix Plus with ROX (Solis BioDyne, Tartu, Estonia), 1.5 μM of Syto 9 (Invitrogen, Carlsbad, CA) and 
2–5 ng of genomic DNA. Four primers were used in each reaction to amplify telomere repeats (telg at 200 nM 
and telc at 400 nM) and albumin gene (albugcr2 at 200 nM and albdgcr2 at 400 nM). The real-time PCR experi-
ments were carried out using the sequence detection system (Applied Biosystems Viia-7) using two simultaneous 
programs to acquire the respective Ct values for telomere repeats and albumin (control) gene. The conditions 
for amplification of telomere repeats were 95 °C/15 min, 2 cycles of 95 °C/20 sec and 49 °C/1 min, followed by 
25 cycles of 85 °C/20 sec with signal acquisition at 59 °C/30 sec. Thermal conditions for albumin gene were 35 
cycles of 95 °C/15 sec, 85 °C/30 sec, with signal acquisition at 84 °C/30 sec. The specificity of all amplifications was 
determined by melting curve analysis done at default settings (95 °C/15 sec, 60 °C/1 min with continuous signal 
acquisition at 0.05 °C/sec ramping, 95 °C/15 sec). The efficiency of PCR amplification and T and S values for each 
sample were determined from the respective standard curves of telomere and albumin reactions. The RTL was 
expressed as the ratio between T/S by taking mean of the triplicate values for each sample. Inter-assay variation 
N Dead HR (95% CI) P
Telomere length
Long (T/S ratio > 1.20) 290 18 ref
Short (T/S ratio ≤ 1.20) 308 36 1.79 (1.01–3.17) 0.05
Composite genetic risk score (continuous) 598 54 2.89 (1.26–6.59) 0.01
Sex
Males 254 33 ref
Females 344 21 0.49 (0.27–0.87) 0.02
Tumor location
Axial 326 34 ref
Extremities 228 12 0.60 (0.30–1.19) 0.14
Acral/Mucosal 44 8 2.34 (1.03–5.31) 0.04
Tumor stage*
1 (1A, 1B) 436 22 ref
2 (2A, 2B, 2C) 162 32 3.60 (2.05–6.30) <0.0001
Table 4. Multivariate analysis of effect of telomere length on melanoma-specific survival in age-matched 
groups. *As tumor stage is defined by Breslow thickness, presence/absence of ulceration and tumor mitotic rate, 
therefore only tumor stage was included in the analysis.
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and intra-assay variation was determined by duplicating the reference DNA for all the dilutions in all the assays 
performed. The PCR efficiencies for telomere and albumin gene assay ranged between 96% and 101%. The inte-
rassay coefficients of variation of the telomere and albumin gene assays were 3.5% and 2.67%, respectively. The 
intra-assay coefficients of variations of the telomere and albumin gene assays were 1.04% and 0.55%, respectively.
Statistical analysis. Differences between the patient groups with short and long telomeres were assessed 
using chi-square test for categorical variables or two sample t-tests for continuous variables. The differences in tel-
omere length in different sample batches procured at different time points were assessed using one-way ANOVA 
in generalized linear model. All the statistical tests were two-sided and P < 0.05 was considered significant. The 
telomere length as T/S ratio was taken as continuous variable (with and without log-transformation) or as cat-
egorical variable. The telomere length was dichotomized based on the median distribution, with patients with 
T/S ratio ≤ 1.20 categorized as the group with ‘short telomeres’ and those with T/S > 1.20 as the group with ‘long’ 
telomeres. Alternatively, patients were grouped into quartiles based on telomere length with T/S 0.48–0.96 for 
the first quartile, 0.97–1.19 for the second quartile, 1.20–1.48 for the third quartile and 1.49–4.85 for the fourth 
quartile (reference). All the other clinical covariates included in the analysis were categorical variables. Patient age 
was considered as a continuous variable unless otherwise specified.
The Kaplan–Meier method was employed to draw the cumulative survival curves using time period (in 
months) between the date of diagnosis and the date of cause-specific death (death from melanoma). The patients 
alive at the end of follow-up period and patients that died from other causes were censored. Death from mela-
noma was confirmed in most patients by the specialists in charge (E.N. and V.S.), who followed them until the 
date of death. In a few remaining patients, mainly people living far from the Institute and who spent their last days 
at home or at the regional hospital, the cause of death was assessed by phone contact with the personnel in charge 
of the palliative care unit in the area.
Statistical differences between the groups were analyzed by the log-rank test. The association of the independent 
variables with melanoma specific patient survival was assessed using univariate methods. Hazard ratios (HRs) and 
95% confidence intervals (95% CI) were estimated in Cox regression models. For multivariate analysis, the variables 
that associated statistically significantly (P < 0.05) in univariate analysis, were included in the model. The patient 
survival time and age were inversely correlated (censored/alive, estimate: −1.08, P > 0.0001; dead, estimate: −1.11, P 
0.0004). To measure the telomere length and age interaction on patient survival, a Cox regression model was imple-
mented using telomere length and age as main effects and telomere length*age as interaction effect. For this purpose, 
patient cohort was divided into 7 quantiles, each representing a 10-year interval based on patient age at diagnosis 
(1st quantile: <30 years, 2nd quantile: 30–40 years, 3rd quantile: 40–50 years, 4th quantile: 50–60 years, 5th quantile: 
60–70 years, 6th quantile: 70–80 years and 7th quantile: >80 years). The telomere length was dichotomized into long 
and short telomeres based on the median telomere length (T/S ratio) for each quantile. In Cox regression model, 
telomere length and age were considered as dichotomous and ordinal variable, respectively.
Additionally, to minimize the confounder effect of age in determining the effect of telomere length on patient sur-
vival, the two groups of patients with, short (median ≤1.20) and long (>1.20) telomeres were matched for age. Before 
matching, the number of patients in “short” and “long” telomere group was 517 and 478 with median age 57 years (IQR: 
46–68) and 46 years (IQR: 35–61), respectively. To make the groups comparable, an exact matching was carried out 
using Proc SQL in SAS and the “long” and “short” groups of patients were considered as controls and cases, respectively. 
The data used for this purpose contained three variables – patient identification, short/long telomeres, and the age at 
diagnosis. The method of matching was based on (1) for each study case, control cases are matched for age; (2) if a 
control matched with more than one case, one control was randomly selected; (3) randomly selected desired number 
of controls for each case. The matching resulted in two identical groups with respect to age, each with 338 patients 
(Median: 52 years, IQR: 41–65). The method implemented was based on Kawabata et al. (2004) Proceedings of the 
Twenty-Ninth Annual SAS Users Group International Conference. Cary, NC: SAS Institute Inc.
To determine the effect of polymorphisms on patient survival, the genotype data were analyzed under the addi-
tive, dominant and recessive models. The polymorphisms were categorized into carriers and non-carriers based on 
the association of alleles with short telomeres. Further, a weighted genetic risk score was calculated for the three gen-
otypes of each polymorphism from Cox regression analysis. Using homozygous common genotype as the reference, 
the beta coefficients for the other two genotypes (heterozygote and homozygous variant genotypes) were calculated 
from Cox regression analysis and used as the corresponding weight. Only patients with complete genotype data for 
three polymorphisms were included for computing weighted score. The weighted genetic risk score thus calculated 
for all three SNPs was summed for each individual based on their genotypes to get composite genetic risk score for 
that individual. The composite genetic risk score was subsequently implemented in the analyses as a continuous var-
iable in the multivariate analyses. To analyze the combined genetic effect and telomere length on survival, patients 
were categorized into 4 categories as high risk (composite genetic risk score >0) and long telomeres (median >1.20), 
high risk (composite genetic risk score >0) and short telomeres (median ≤1.20), low risk (composite genetic risk 
score ≤0) and long telomeres (median >1.20), low risk (composite genetic risk score ≤0) and short telomeres 
(median ≤1.20). All statistical analyses were carried out using SAS version 9.4 (SAS Institute Inc., Cary, NC).
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